Nivolumab Maintenance for Aggressive B‐Cell Lymphoma in Remission After First Line Therapy: A Phase 2 Clinical Trial

Documenti analoghi

• Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)—An open‐label, phase I/II study
  di: Ivetta Danylesko, et al.
  Pubblicazione: (2025)
• A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B‐Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation
  di: Aseel Alsouqi, et al.
  Pubblicazione: (2025)
• Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B‐Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review
  di: Bastian von Tresckow, et al.
  Pubblicazione: (2025)
• Biological Findings and Clinical Outcomes in Patients Treated With R‐CHOP Plus High‐Dose Methotrexate as First‐Line Therapy in Large B‐Cell Lymphoma With Testis Involvement
  di: R. Liévin, et al.
  Pubblicazione: (2024)
• Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia
  di: Baohang Zhang, et al.
  Pubblicazione: (2025)